|
KMID : 1101820160040020116
|
|
Journal of Breast Disease
2016 Volume.4 No. 2 p.116 ~ p.121
|
|
|
Oncologic Effect of Oral Fluorouracil in Hormone Receptor-Negative T1a Node-Negative Breast Cancer Patients
|
|
Kim Min-Sung
Ahn Sei-Hyun
Son Byung-Ho
Lee Jong-Won
Koh Bum-Seok
Sohn Gui-Yeon
Lee Sae-Byeol
Kim Hee-Jeong
|
|
|
Abstract
|
|
|
Purpose: As 5-fluorouracil (5-FU) has previously exhibited antitumor activity and few adverse effects in the treatment of breast cancer, we aimed to specifically assess the benefits of orally administered 5-FU in hormone receptor-negative small breast cancer.
Methods: We retrospectively identified patients with pT1aN0 and hormone receptor-negative breast cancer who underwent surgery between 1993 and 2008 at Asan Medical Center. Patients were divided into two cohorts based on adjuvant doxifluridine (Didox; Shin Poong Pharm. Co., Ltd.) administration, and the disease-free survival (DFS) and cancer-specific survival (CSS) was assessed for each cohort.
Results: Both cohorts had similar ages and tumor sizes. The DFS and CSS did not significantly differ between the groups (p=0.399 and p=0.126, respectively). When the cohorts were assessed according to human epidermal growth factor receptor 2 (HER2) status, doxifluridine significantly improved DFS among patients with T1aN0 and HER2-positive breast cancer (p=0.037).
Conclusion; Doxifluridine did not yield a significant reduction in DFS events in hormone receptor-negative early breast cancer. However, a clear benefit was observed in hormone receptor-negative, HER2-positive T1aN0 breast cancer patients.
|
|
|
KEYWORD
|
|
|
Breast neoplasms, Doxifluridine, Hormone receptor, Human epidermal growth factor receptor 2, Small tumor
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
 
|